Hemolytic Disease of The Newborn

Hemolytic disease of the newborn (HDN), or erythroblastosis fetalis, primarily impacts rhesus-positive fetuses born to rhesus-negative mothers. The condition arises when maternal antibodies, formed after alloimmunization due to rhesus or ABO blood type incompatibility, attack fetal red blood cells. Historically, HDN was associated with a fetal death rate of about 1% in pregnancies. However, advancements in immunoprophylactic treatments have significantly improved management and outcomes when the condition is diagnosed early. Diagnosis involves a comprehensive assessment, including patient history, physical exams, serological tests, and imaging, such as pelvic ultrasound. Preventative measures, like administering intravenous immunoglobulin (IVIG) to unsensitized Rh-negative mothers, are crucial. Understanding potential complications, particularly severe hyperbilirubinemia, is also essential for effective treatment. With ongoing research, the understanding of HDN continues to evolve, leading to better management strategies and outcomes in clinical practice. This review discusses the etiology, diagnosis, and current management approaches for HDN, highlighting recent findings and future directions for research. Since the identification of the Rh blood group system in 1940, there has been an improved understanding of hemolytic disease of the fetus and newborn (HDFN).